Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …

The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic
function and axonal structure over the course of Alzheimer's disease. Here, we assessed …

Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Animal models are indispensable tools for Alzheimer disease (AD) research. Over the
course of more than two decades, an increasing number of complementary rodent models …

In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in
life. This observation resulted in a sea-change in how researchers viewed aging. This was …

Topic OCT is a noninvasive tool to measure specific retinal layers in the eye. The
relationship of retinal spectral-domain (SD) OCT measurements with Alzheimer's disease …

A major obstacle in Alzheimer's disease (AD) research is the lack of predictive and
translatable animal models that reflect disease progression and drug efficacy. Transgenic …

Alzheimer's disease is the most common form of dementia, characterized by two
pathological hallmarks: amyloid-β plaques and neurofibrillary tangles. The amyloid …